Serum dihydroxyacetone kinase peptide m/z 520.3 as predictor of disease severity in patients with compensated chronic hepatitis B

BACKGROUND & AIM: Due to known limitations of liver biopsy, reliable non-invasive serum biomarkers for chronic liver diseases are needed. We performed serum peptidomics for such investigation in compensated chronic hepatitis B (CHB) patients. METHODS: Liquid chromatography combined with tandem m...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ming-Yi, Jia, Xiao-Fang, Qu, Ying, Zheng, Rui-Dan, Yuan, Zheng-Hong, Weng, Hong-Lei, Dooley, Steven, Wang, Xing-Peng, Zhang, Li-Jun, Lu, Lun-Gen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851457/
https://www.ncbi.nlm.nih.gov/pubmed/24289155
http://dx.doi.org/10.1186/1479-5876-11-234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851457/
https://www.ncbi.nlm.nih.gov/pubmed/24289155
http://dx.doi.org/10.1186/1479-5876-11-234

Ejemplares similares